Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on December 3, 2025, and filed on December 4, 2025. The Company, a foreign private issuer, executed a share repurchase through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase event rather than comprehensive financial statements. Key metrics for the transaction on December 3, 2025, include:
- Shares Purchased: 218,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,830.00p; highest price paid was 1,848.00p.
- Average Price: Volume-weighted average price paid was 1,839.30p.
- Trading Venues: Purchases were executed across BATE (24,080 shares), CHIX (62,312 shares), and XLON (131,608 shares).
Since the programme's inception on September 30, 2025, the Company has purchased an aggregate of 11,764,733 ordinary shares. Following this transaction, the Company holds 237,229,577 ordinary shares in treasury. The total number of ordinary shares in issue (excluding treasury shares) is 4,078,204,107, representing the total voting rights.
Material Changes and Capital Structure
The primary material change reported is the reduction of shares in issue and the increase in treasury shares. The percentage of voting rights attributable to ordinary shares held in treasury is now 5.82 per cent. This figure is critical for shareholders determining notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The filing does not report changes to revenue, profit, or debt levels, as it is a transaction-specific report.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the Company's 2024 Annual Report on Form 20-F and Q3 2025 Results. The purchase was effected pursuant to a non-discretionary agreement, indicating a structured approach to capital return.
Important Facts for Investor Verification
- Verify the total treasury share count of 237,229,577 and the 5.82% voting rights threshold for disclosure obligations.
- Confirm the remaining capacity under the buyback programme announced on September 30, 2025, as 11.76 million shares have been repurchased to date.
- Note that the transaction price (approx. 1,839p) reflects market conditions on December 3, 2025, across multiple trading venues.
- Review the referenced 2024 Form 20-F and Q3 2025 Results for broader risk factors and financial context not included in this transaction report.